Genmab's H1 Preview: Darzalex Beats The Sales Outlook

Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference price. DARZALEX H1 sales reached $8.17B, already exceeding half of Genmab’s $16.0B full-year assumption. Holding Q2 sales flat through H2 would produce $16.59B, above the $16.4B high end of guidance. Tiered DARZALEX royalties should rise from 14.2% in Q1 toward roughly 16.9% for the full year. Main risks are premium valuation, DARZALEX concentration, $3.69B net debt, weak cash conversion, and pipeline failure. Genmab receives a royalty on every dollar that J&J sells of DARZALEX, and about two-thirds This article was written by Maxell Agustin Aguiran 6 Followers Follow Maxell Agustin Aguiran is an equity research analyst focused on fundamental investing, valuation, and quantitative analysis. His research emphasizes identifying undervalued companies, potential value traps, and asymmetric investment opportunities through detailed analysis of financial statements, SEC filings, earnings reports, and industry trends. Drawing on a background in finance and a disciplined, data-driven investment process, he develops independent, evidence-based investment theses that prioritize business fundamentals, valuation, and risk. His goal is to provide objective analysis that helps investors distinguish market sentiment from intrinsic value. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.